NLS Pharmaceutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

NLS Pharmaceutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-21.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-21.2%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

NLS Pharmaceutics gets delisting determination letter from Nasdaq

Oct 05

NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate

Sep 27

NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders

Jul 28

Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation

Mar 04

Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky

Nov 12

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NLSP şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NLSP şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

NLS Pharmaceutics Piyasaya Karşı Temettü Getirisi

NLSP temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NLSP)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (NLSP) (3 yıla kadar)	n/a

Önemli Temettü: NLSP şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NLSP şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NLSP şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NLSP herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

NLS Pharmaceutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

NLS Pharmaceutics Ltd. Highlights Innovative Preclinical Program for First-In-Class Non-Sulfonamide Dual Orexin Receptor Agonists (Doxa) in Narcolepsy and Neurological Disorders

NLS Pharmaceutics AG Announces Resignation of Claudio Bassetti as Member of the Board

NLS Pharmaceutics Regains Full Compliance with Nasdaq Listing Requirements

NLS Pharmaceutics Expects it Regains Compliance with Nasdaq Minimum Bid Price and Stockholders' Equity Requirements

NLS Pharmaceutics AG Announces Termination of Elena Thyen as Chief Financial Officer, Effective October 31, 2024

Kadimastem Ltd (TASE:KDST) signed a letter of intent to acquire NLS Pharmaceutics AG (NasdaqCM:NLSP) in a reverse merger transaction.

NLS Pharmaceutics Ltd. Announces Promising Preclinical Results for Parkinson's Disease Treatments

NLS Pharmaceutics AG, Annual General Meeting, Jun 27, 2024

NLS Pharmaceutics AG Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (Doxa)

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

NLS Pharmaceutics Ltd. announced delayed 20-F filing

NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding

NLS Pharmaceutics Ltd. has filed a Follow-on Equity Offering in the amount of $1.75 million.

NLS Pharmaceutics Ltd. has filed a Follow-on Equity Offering in the amount of $1.75 million.

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

NLS Pharmaceutics Ltd. Approves Board Appointments

NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol

NLS Pharmaceutics AG, Annual General Meeting, Jun 30, 2023

New major risk - Shareholder dilution

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

NLS Pharmaceutics Ltd. Announces the Resignation of Chad Hellmann as Chief Financial Officer

NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement

NLS Pharmaceutics Ltd. Announces New in Vitro Study Results Demonstrating the Agonist Effect of Mazindol ER At the Orexin-2 Receptor

NLS Pharmaceutics Ltd Announces an R&D Update Webcast to Review It’S Growing Portfolio of Pre-Clinical Compounds

NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037

NLS Pharmaceutics AG announced that it expects to receive $30 million in funding from BVF Partners L.P.

NLS Pharmaceutics AG Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder

NLS Pharmaceutics Ltd. Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe

NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice

NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq

NLS Pharmaceutics gets delisting determination letter from Nasdaq

NLS Pharmaceutics Ltd. Announces Positive Top-Line Results from Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate

NLS Pharmaceutics Ltd. Announces Management Changes

Price target decreased to US$8.63

NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders

NLS Pharmaceutics Ltd. Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia

NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification

NLS Pharmaceutics AG Appoints Chad C. Hellmann as Chief Financial Officer

NLS Pharmaceutics AG, Annual General Meeting, May 31, 2022

Price target decreased to US$7.50

NLS Pharmaceutics AG Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER

Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation

NLS Pharmaceutics to Present Interim Top-Line Data for Quilience® (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022

Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky

NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating Narcolepsy

NLS Pharmaceutics AG announced delayed 20-F filing

NLS Pharmaceutics AG Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex

NLS Pharmaceutics AG Announces Change in Company’s Executive Management Team

Independent Director has left the company

NLS Pharmaceutics AG Announces Resignation of Pascal Brenneisen as A Member of the Board of Director

NLS Pharmaceutics Ltd. Approves Board and Committee Appointments

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin